Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. Recruits DNA helicase MCM9 to chromatin which unwinds the mismatch containg DNA strand. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis.
Background References
1. Kansikas M. et al. Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants. Hum. Mutat. 32:107-115(2011).
2. Traver S. et al. MCM9 Is Required for Mammalian DNA Mismatch Repair. Mol. Cell 59:831-839(2015).
Sequence Similarity
Belongs to the DNA mismatch repair MutS family.
Tissue Specificity
Ubiquitously expressed.
Post-translational Modification
Phosphorylated by PRKCZ, which may prevent MutS alpha degradation by the ubiquitin-proteasome pathway.
Western blot analysis of MSH2 on different lysates with Rabbit anti-MSH2 antibody (ER1803-86) at 1/5,000 dilution.
Lane 1: HeLa (Human cervical adenocarcinoma cell) cell lysate (15 µg/Lane) Lane 2: HEK-293 (Human embryonic kidney cell) cell lysate (15 µg/Lane) Lane 3: LNCaP (Human prostate cancer cell) cell lysate (15 µg/Lane) Lane 4: NIH/3T3 (Mouse fibroblast) cell lysate (15 µg/Lane) Lane 5: Mouse testis tissue lysate (30 µg/Lane) Lane 6: Rat testis tissue lysate (30 µg/Lane)
Exposure time: 6 seconds; ECL: K1801
LNCaP is a negative control (PMID: 11025778).
Blocking: 5% NFDM/TBST, 1 hour at room temperature Primary antibody: ER1803-86, 1/5,000 in primary antibody dilution buffer (K1803), overnight at 4 ℃ Secondary antibody: Goat anti-Rabbit IgG-HRP (HA1001), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature
Predicted band size: 104 kDa Observed band size: 104 kDa
☑ Knockout (KO)
All lanes: Western blot analysis of MSH2 with anti-MSH2 antibody (ER1803-86) at 1:1,000 dilution. Lane 1: Wild-type SCC7 whole cell lysate. Lane 2: MSH2 knockout SCC7 whole cell lysate.
ER1803-86 was shown to specifically react with MSH2 in wild-type SCC7 cells. No band was observed when MSH2 knockout samples were tested. Wild-type and MSH2 knockout samples were subjected to SDS-PAGE. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM in TBST for 1 hour at room temperature. The primary Anti-MSH2 antibody (ER1803-86, 1/1,000) and Anti-HSP90 antibody (ET1605-56, 1/10,000) were used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG H&L (HRP) Secondary Antibody (HA1001) at 1:200,000 dilution was used for 1 hour at room temperature.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"